Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.85 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3834596 | 0.95 | F10 (0.88) | F10HTTTSHRALDH1A1NPSR1 | |
| SCHEMBL3834412 | 0.92 | F10 (1.00) | F10TSHRALDH1A1NPSR1TDP1 | |
| SCHEMBL3835405 | 0.92 | F10 (1.00) | F10TSHRALDH1A1NPSR1TDP1 | |
| SCHEMBL3832113 | 0.92 | F10 (1.00) | F10TSHRALDH1A1NPSR1TDP1 | |
| SCHEMBL3832134 | 0.92 | F10 (0.88) | F10TSHRALDH1A1NPSR1TDP1 | |
| SCHEMBL3834482 | 0.91 | F10 (0.85) | F10TSHRALDH1A1NPSR1TDP1 | |
| SCHEMBL3835445 | 0.90 | F10 (0.87) | F10TSHRALDH1A1NPSR1TDP1 | |
| SCHEMBL3828989 | 0.90 | F10 (0.86) | F10TSHRALDH1A1NPSR1TDP1 | |
| SCHEMBL3830323 | 0.89 | F10 (0.80) | F10TSHRALDH1A1NPSR1TDP1 | |
| SCHEMBL3834651 | 0.89 | F10 (0.85) | F10TSHRALDH1A1NPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | claimed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | claimed |
| EP-1465864-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | Warner-Lambert Company LLC (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2003045912-A1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | claimed |
| EP-2085391-A2 | Inhibitors of factor XA and other serine proteases involved in the coagulation cascade | Warner-Lambert Company LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | WARNER-LAMBERT COMPANY LLC | 2008-11-20 | — | — | US | disclosed |
| US-7407974-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1671949-B1 | Substituted Pyridinylamines | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1671949-A2 | Substituted phenylamines and pyridinylamines | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7030141-B2 | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER-LAMBERT COMPANY LLC | 2006-04-18 | — | — | US | disclosed |
| EP-1465864-B1 | INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE | WARNER LAMBERT CO (US) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287674-A1 | Inhibitors of Factor XA and Other Serine Proteases Involved in the Coagulation Cascade | TFPI, F11, F2 | F10 11/4885HTT 4489/4885TSHR 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.